ME03713B - Bardoksolon meтil za lečenje gojaznosтi - Google Patents
Bardoksolon meтil za lečenje gojaznosтiInfo
- Publication number
- ME03713B ME03713B MEP-2020-4A MEP420A ME03713B ME 03713 B ME03713 B ME 03713B ME P420 A MEP420 A ME P420A ME 03713 B ME03713 B ME 03713B
- Authority
- ME
- Montenegro
- Prior art keywords
- patient
- compound
- use according
- disease
- diagnosed
- Prior art date
Links
- WPTTVJLTNAWYAO-KPOXMGGZSA-N Bardoxolone methyl Chemical compound C([C@@]12C)=C(C#N)C(=O)C(C)(C)[C@@H]1CC[C@]1(C)C2=CC(=O)[C@@H]2[C@@H]3CC(C)(C)CC[C@]3(C(=O)OC)CC[C@]21C WPTTVJLTNAWYAO-KPOXMGGZSA-N 0.000 title 1
- 208000008589 Obesity Diseases 0.000 title 1
- 235000020824 obesity Nutrition 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 25
- 208000020832 chronic kidney disease Diseases 0.000 claims 4
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 2
- 208000002705 Glucose Intolerance Diseases 0.000 claims 2
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims 2
- 206010022489 Insulin Resistance Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 229920001577 copolymer Polymers 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 208000033679 diabetic kidney disease Diseases 0.000 claims 2
- 208000010706 fatty liver disease Diseases 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 229910016523 CuKa Inorganic materials 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 238000002441 X-ray diffraction Methods 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 239000000090 biomarker Substances 0.000 claims 1
- 239000006185 dispersion Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 239000013585 weight reducing agent Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Child & Adolescent Psychology (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Claims (21)
1. Jedinjenje iz formule: za upotrebu za terapijsko smanjenje tei:ine humanog pacijenta kom je potrebno.
2. Jedinjenje za upotrebu prema patentnom zahtevu 1, pri cemu:(a) pacijentu nije dijagnostikovano hronicno oboljenje bubrega (CKO); iii(b) pacijentu nije dijagnostikovana dijabetesna nefropatija (ON).
3. Jedinjenje za upotrebu prema patentnom zahtevu 1, pri cemu: (a) pacijent nema hronicno oboljenje bubrega (CKO);(b) pacijent ne boluje od renalnog oboljenja; iii(c) pacijent nema dijabetesnu nefropatiju (ON).
4.Jedinjenje za upotrebu prema patentnom zahtevu 1, pri cemu: (a) pacijentu nije dijagnostikovan dijabetes;(b) pacijentu nije dijagnostikovana insulinska rezistencija; iii(c) pacijentu nije dijagnostikovana netolerancija na glukozu.
5.Jedinjenje za upotrebu prema patentnom zahtevu 1, pri cemu:(a) pacijent nema dijabetes;(b) pacijent nema insulinsku rezistenciju; iii1(c) pacijent nema netoleranciju na glukozu.
6.Jedinjenje za upotrebu prema patentnom zahtevu 1, pri cemu pacijentu nije dijagnostikovano kardiovaskularno oboljenje.
7.Jedinjenje za upotrebu prema patentnom zahtevu 1, pri cemu pacijent nema kardiovaskularno oboljenje.
8.Jedinjenje za upotrebu prema patentnom zahtevu 1, pri cemu pacijentu nije dijagnostikovano oboljenje masne jetre.
9.Jedinjenje za upotrebu prema patentnom zahtevu 1, pri cemu pacijent nema oboljenje masne jetre.
10. Jedinjenje za upotrebu prema patentnom zahtevu 1, pri cemu pacijent nema povisene nivoe barem jednog biomarkera povezanog sa metabolickim sindromom.
11.Jedinjenje za upotrebu prema patentnom zahtevu 1, pri cemu pacijentu nije dijagnostikovan kancer.
12.Jedinjenje za upotrebu prema patentnom zahtevu 1, pri cemu pacijent nema kancer.
13.Jedinjenje za upotrebu prerna patentnom zahtevu 1, pri cemu:(a) pacijent ne boluje od autoimunog oboljenja; (b) pacijent ne boluje od respiratornog oboljenja;(c) pacijent ne boluje od neurodegenerativnog oboljenja; (d) pacijent ne boluje od bolesti jetre; iii(e) pacijent ne boluje od infektivne bolesti.
14.Jedinjenje za upotrebu prema patentnom zahtevu 1, pri cemu je pacijent gojazan.
15. Jedinjenje za upotrebu prema patentnom zahtevu 1, pri cemu je barem deo jedinjenja prisutan kao amorfni oblik koji ima obrazac rendgenske difrakcije(CuKa) sa halo vrsnom vrednoscu na priblizno 13,5 °29, i Tg od oko 120 oc dooko 135 °C.
16. Jedinjenje za upotrebu prema bilo kom od patentnih zahteva 1 do 15, pri cemu se to jedinjenje isporucuje u dnevnoj dozi od 5 mg do 50 mg.
17.Jedinjenje za upotrebu prema patentnom zahtevu 16, pri cemu je ta dnevna doza oko 10 mg, oko 20 mg, iii oko 40 mg.
18. Upotreba jedinjenja kako je definisano u patentnom zahtevu 1 iii patentnom zahtevu 15 za proizvodnju leka za terapijsko smanjenje tezine humanog pacijenta kako je definisano u bilo kom od patentnih zahteva 1 do 14.
19. Jedinjenje za upotrebu prema patentnom zahtevu 1, pri cemu je to jedinjenje formulisano kao disperzija u cvrstom obliku koja obuhvata jedinjenje iz patentnog zahteva 1 i neki ekscipijent.
20. Jedinjenje za upotrebu prema patentnom zahtevu 19, pri cemu je taj ekscipijent metakrilna kiselina -etil akrilat kopolimer.
21.Jedinjenje za upotrebu prema patentnom zahtevu 20, pri cemu je odnos u metakrilna kiselina -etil akrilat kopolimeru 1:1.3
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32327610P | 2010-04-12 | 2010-04-12 | |
| US38909010P | 2010-10-01 | 2010-10-01 | |
| PCT/US2011/032156 WO2011130302A2 (en) | 2010-04-12 | 2011-04-12 | Method of treating obesity using antioxidant inflammation modulators |
| EP11715645.5A EP2558105B1 (en) | 2010-04-12 | 2011-04-12 | Bardoxolone methyl for the treatment of obesity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME03713B true ME03713B (me) | 2021-01-20 |
Family
ID=44259866
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2020-4A ME03713B (me) | 2010-04-12 | 2011-04-12 | Bardoksolon meтil za lečenje gojaznosтi |
Country Status (31)
| Country | Link |
|---|---|
| US (3) | US10105372B2 (me) |
| EP (1) | EP2558105B1 (me) |
| JP (1) | JP5990160B2 (me) |
| KR (1) | KR101819699B1 (me) |
| CN (1) | CN102939089B (me) |
| AU (1) | AU2011240690C1 (me) |
| BR (1) | BR112012026112B1 (me) |
| CA (1) | CA2795320C (me) |
| CL (1) | CL2012002859A1 (me) |
| CY (1) | CY1122480T1 (me) |
| DK (1) | DK2558105T3 (me) |
| EA (1) | EA026567B1 (me) |
| ES (1) | ES2768204T3 (me) |
| HR (1) | HRP20192291T1 (me) |
| HU (1) | HUE047994T2 (me) |
| IL (1) | IL222273B (me) |
| LT (1) | LT2558105T (me) |
| ME (1) | ME03713B (me) |
| MX (1) | MX357596B (me) |
| MY (1) | MY163031A (me) |
| NZ (1) | NZ602826A (me) |
| PH (1) | PH12012502041B1 (me) |
| PL (1) | PL2558105T3 (me) |
| PT (1) | PT2558105T (me) |
| RS (1) | RS59850B1 (me) |
| SG (2) | SG184830A1 (me) |
| SI (1) | SI2558105T1 (me) |
| SM (1) | SMT202000086T1 (me) |
| TW (1) | TWI558724B (me) |
| WO (1) | WO2011130302A2 (me) |
| ZA (1) | ZA201207518B (me) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6326507B1 (en) | 1998-06-19 | 2001-12-04 | Trustees Of Dartmouth College | Therapeutic compounds and methods of use |
| KR101780382B1 (ko) | 2008-01-11 | 2017-10-10 | 리타 파마슈티컬스 잉크. | 합성 트리테르페노이드 및 질병 치료시의 사용 방법 |
| RS58392B1 (sr) | 2008-04-18 | 2019-04-30 | Reata Pharmaceuticals Inc | Antioksidantni modulatori inflamacije: derivati oleanoličke kiseline sa amino i drugim modifikacijama na c-17 |
| CN103588678A (zh) | 2008-04-18 | 2014-02-19 | 里亚塔医药公司 | 包含抗炎症药效团的化合物以及使用方法 |
| RS55631B1 (sr) | 2008-04-18 | 2017-06-30 | Reata Pharmaceuticals Inc | Antioksidansni modulatori upale: c-17 homologisani derivati oleanolinske kiseline |
| CN102164941B (zh) | 2008-04-18 | 2015-05-27 | 里亚塔医药公司 | 抗氧化剂炎症调节剂:具有饱和c环的齐墩果酸衍生物 |
| AU2009274037B2 (en) | 2008-07-22 | 2015-07-09 | Trustees Of Dartmouth College | Monocyclic cyanoenones and methods of use thereof |
| AU2011240690C1 (en) * | 2010-04-12 | 2014-11-06 | Reata Pharmaceuticals Holdings, LLC | Method of treating obesity using antioxidant inflammation modulators |
| CA2822071C (en) | 2010-12-17 | 2019-07-16 | Reata Pharmaceuticals, Inc. | Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators |
| PL2683731T3 (pl) | 2011-03-11 | 2019-09-30 | Reata Pharmaceuticals, Inc. | C4-monometylowe pochodne triterpenoidów i sposoby ich zastosowania |
| KR101174701B1 (ko) * | 2011-12-29 | 2012-08-17 | 서울대학교산학협력단 | 진저레논 에이를 포함하는 비만 예방용 식품 조성물, 비만 치료용 약학조성물 및 비만 치료용 동물용 의약품 |
| WO2013163344A1 (en) | 2012-04-27 | 2013-10-31 | Reata Pharmaceuticals, Inc. | 2.2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof |
| US9556222B2 (en) | 2012-06-15 | 2017-01-31 | Reata Pharmaceuticals, Inc. | A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof |
| WO2014040073A1 (en) | 2012-09-10 | 2014-03-13 | Reata Pharmaceuticals, Inc. | C13-hydroxy derivatives of oleanolic acid and methods of use thereof |
| US9512094B2 (en) | 2012-09-10 | 2016-12-06 | Reata Pharmaceuticals, Inc. | C17-heteroaryl derivatives of oleanolic acid and methods of use thereof |
| CA2884400A1 (en) * | 2012-09-10 | 2014-03-13 | Abbvie Inc. | Glycyrrhetinic acid derivatives and methods of use thereof |
| AU2013312106B2 (en) | 2012-09-10 | 2018-03-08 | Reata Pharmaceuticals, Inc. | C17-alkanediyl and alkenediyl derivatives of oleanolic acid and methods of use thereof |
| HRP20181879T1 (hr) | 2012-09-27 | 2019-02-08 | The Children's Medical Center Corporation | Spojevi za liječenje pretilosti i postupci za njihovu upotrebu |
| JP6328102B2 (ja) | 2013-03-19 | 2018-05-23 | 第一三共株式会社 | テルペノイド誘導体 |
| TWI649330B (zh) * | 2013-04-24 | 2019-02-01 | 艾伯維有限公司 | 甲基巴多索龍之２，２－二氟丙醯胺衍生物、其多晶形及其使用方法 |
| CN112870202A (zh) * | 2013-08-23 | 2021-06-01 | 里亚塔医药公司 | 使用甲基巴多索隆或其类似物治疗和预防肾病的方法 |
| MX372772B (es) | 2014-01-24 | 2020-06-29 | Reata Pharmaceuticals Inc | Enonas piridazolilo y pirimidinilo tricíclicas sustituidas con arilo y arilalquilo como moduladores de la inflamación antioxidantes. |
| AU2015256178B2 (en) | 2014-05-05 | 2020-02-27 | The Board Of Regents Of The University Of Texas System | Methods and compositions comprising ursolic acid and/or resveratrol for treating obesity, diabetes, or cancer |
| US10208082B2 (en) | 2014-09-10 | 2019-02-19 | Daiichi Sankyo Company, Limited | Sustained-release pharmaceutical composition for treatment and prevention of eye disease |
| JP6748652B2 (ja) | 2015-02-12 | 2020-09-02 | リアタ ファーマシューティカルズ インコーポレイテッド | 抗酸化性炎症調節剤としてのイミダゾリル三環式エノン |
| CN105017374B (zh) * | 2015-07-20 | 2017-03-01 | 山西大学 | 一种齐墩果酸内酯类衍生物及其制备方法和应用 |
| US20170056373A1 (en) * | 2015-09-01 | 2017-03-02 | Syracuse University | Ghrelin o-acyltransferase inhibitors |
| NZ741082A (en) | 2015-09-23 | 2023-06-30 | Reata Pharmaceuticals Inc | C4-modified oleanolic acid derivatives for inhibition of il-17 and other uses |
| EP3509699A4 (en) * | 2016-09-08 | 2020-05-06 | Regenera Pharma Ltd. | COMPOSITIONS WITH TRITER PENOIDS AND USES THEREOF FOR TREATING OPTICAL NEUROPATHY |
| MX2019005401A (es) | 2016-11-08 | 2019-08-05 | Reata Pharmaceuticals Inc | Metodos para tratar el sindrome de alport con bardoxolona metilo o analogos de la misma. |
| TWI831738B (zh) | 2016-12-16 | 2024-02-11 | 美商瑞塔醫藥有限責任公司 | 用於抑制ＲＯＲγ及其他用途的嘧啶三環烯酮衍生物 |
| CA3103726A1 (en) | 2018-06-15 | 2019-12-19 | Reata Pharmaceuticals, Inc. | Pyrazole and imidazole compounds for inhibition of il-17 and rorgamma |
| EP3810141A1 (en) | 2018-06-20 | 2021-04-28 | Reata Pharmaceuticals, Inc. | Cysteine-dependent inverse agonists of nuclear receptors ror-gamma/ror-gamma-t and methods of treating diseases or disorders therewith |
| CA3144603C (en) | 2019-07-19 | 2025-10-21 | Reata Pharmaceuticals, Inc. | C17 Polar Substitution Heteroaromatic Synthetic Triterpenoids and Their Methods of Use |
| WO2021222424A1 (en) * | 2020-04-29 | 2021-11-04 | BioAge Labs, Inc. | Hypoxia-inducible factor prolyl hydroxylase inhibitors for treating aging-related conditions |
| AU2021273460A1 (en) * | 2020-05-09 | 2022-12-08 | Reata Pharmaceuticals Holdings, LLC | Methods of treating covid-19 using bardoxolone methyl or analogs thereof |
| EP4642462A1 (en) * | 2022-12-29 | 2025-11-05 | The Board Of Regents Of The University Of Texas System | Synthetic triterpenoids and compositions thereof in weight management, skeletal muscle function, and appetite suppression |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4395423A (en) | 1978-10-10 | 1983-07-26 | Sterling Drug Inc. | Polycyclic cyanoketones |
| NZ191586A (en) | 1978-10-10 | 1981-10-19 | Sterling Drug Inc | Cyanoketones derived from glycyrrhetinic acid and pharmaceutical compositions |
| US6025395A (en) | 1994-04-15 | 2000-02-15 | Duke University | Method of preventing or delaying the onset and progression of Alzheimer's disease and related disorders |
| US6326507B1 (en) | 1998-06-19 | 2001-12-04 | Trustees Of Dartmouth College | Therapeutic compounds and methods of use |
| US6369101B1 (en) | 1999-02-26 | 2002-04-09 | Regents Of The University Of Minnesota | Therapeutic method to treat herpes virus infection |
| ES2295031T3 (es) | 1999-05-14 | 2008-04-16 | Nereus Pharmaceuticals, Inc. | Nuevos moduladores de interleucina-1 y factor de necrosis tumoral, sintesis de dichos moduladores y metodos de uso de dichos moduladores. |
| US6890946B2 (en) | 1999-12-23 | 2005-05-10 | Indiana University Research And Technology Corporation | Use of parthenolide to inhibit cancer |
| WO2002003996A1 (en) | 2000-07-12 | 2002-01-17 | RAJKUMAR, Sujatha | Use of dammarane-type tritepenoid saporins |
| JP2004509972A (ja) | 2000-09-29 | 2004-04-02 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | 酵母に対する殺真菌活性を有するトリテルペン |
| US6878751B1 (en) | 2000-10-19 | 2005-04-12 | Imperial College Of Science Technology And Medicine | Administration of resveratrol to treat inflammatory respiratory disorders |
| CA2430454A1 (en) | 2000-11-28 | 2002-06-20 | Board Of Regents, The University Of Texas System | Cddo-compounds and combination therapies thereof |
| US7435755B2 (en) | 2000-11-28 | 2008-10-14 | The Trustees Of Dartmouth College | CDDO-compounds and combination therapies thereof |
| NZ528394A (en) * | 2001-03-23 | 2005-06-24 | Shire Biochem Inc | Pharmaceutical combinations for the treatment of cancer comprising dioxolane analogues and nuceloside analogues and/or chemotherapeutic agents |
| AU2002308701A1 (en) | 2001-05-14 | 2002-11-25 | University Of Maryland, Baltimore | Novel alanine transaminase enzyme and methods of use |
| CA2472581C (en) | 2002-01-15 | 2012-06-26 | Trustees Of Dartmouth College | Tricyclic-bis-enone derivatives and methods of use thereof |
| JP2006515859A (ja) | 2002-05-13 | 2006-06-08 | トラスティーズ オブ ダートマス カレッジ | 阻害剤およびその使用法 |
| EP1457206A1 (en) * | 2003-03-13 | 2004-09-15 | Fournier Laboratories Ireland Limited | Combined use of a fibrate and orlistat for the treatment of obesity |
| US20050014730A1 (en) | 2003-04-02 | 2005-01-20 | Carlson Robert M. | Anti-fungal formulation of triterpene and essential oil |
| JP2007524584A (ja) | 2003-05-09 | 2007-08-30 | ノボ ノルディスク アクティーゼルスカブ | 肥満の治療に使用するペプチド |
| RU2005133970A (ru) * | 2003-05-09 | 2007-06-20 | Ново Нордиск А/С (DK) | Пептиды, применяемые для лечения ожирения |
| EP2218342B1 (en) | 2003-05-27 | 2018-07-04 | DSM IP Assets B.V. | Novel nutraceutical compositions and use thereof |
| WO2005042002A2 (en) | 2003-10-30 | 2005-05-12 | Entelos, Inc. | Treatment of rhematoid arthritis with flip antagonists |
| WO2005046732A2 (en) | 2003-11-04 | 2005-05-26 | THE UNITED SATES OF AMERICA as represented by THE SECRETARY OF HEALTH AND HUMAN SERVICES, NIH | Methods and compositions for the inhibition of hiv-1 replication |
| EP1803468B1 (en) | 2003-12-22 | 2011-09-07 | Novartis AG | Agents for treatment of glaucomatours retinopathy and optic neuropathy |
| JP2005314381A (ja) | 2004-03-30 | 2005-11-10 | Anges Mg Inc | 増殖性腎疾患の予防・治療・改善剤 |
| WO2005113761A2 (en) | 2004-04-19 | 2005-12-01 | University Of Maryland, Baltimore | Novel alanine transaminase enzymes and methods of use |
| US7772195B2 (en) | 2004-07-29 | 2010-08-10 | Board Of Trustees Of Michigan State University | Methods and compositions for the treatment of obesity, insulin related diseases and hypercholesterolemia |
| JP5087400B2 (ja) | 2004-09-07 | 2012-12-05 | パシフィック アロー リミテッド | アンゲロイル基を有する抗腫瘍化合物 |
| WO2007005879A2 (en) | 2005-07-01 | 2007-01-11 | The Johns Hopkins University | Compositions and methods for the treatment or prevention of disorders relating to oxidative stress |
| US20070249561A1 (en) | 2006-04-25 | 2007-10-25 | Taylor Bradley K | Pharmacological method for treatment of neuropathic pain |
| JP5610766B2 (ja) | 2006-06-27 | 2014-10-22 | ウェリントン ラボラトリーズ インコーポレイティッド | グリチルレチン酸誘導体 |
| WO2008016095A1 (en) | 2006-08-02 | 2008-02-07 | Santen Pharmaceutical Co., Ltd. | PREVENTIVE OR REMEDY FOR KERATOCONJUNCTIVAL DISORDERS CONTAINING Nrf2 ACTIVATOR AS THE ACTIVE INGREDIENT |
| JP2008110962A (ja) | 2006-08-02 | 2008-05-15 | Santen Pharmaceut Co Ltd | Ｎｒｆ２活性化物質を有効成分として含む角結膜障害の予防または治療剤 |
| US8299046B2 (en) | 2006-11-17 | 2012-10-30 | Trustees Of Dartmouth College | Synthetic triterpenoids and tricyclic-bis-enones for use in stimulating bone and cartilage growth |
| WO2008064133A1 (en) | 2006-11-17 | 2008-05-29 | Trustees Of Dartmouth College | Synthesis and biological activities of new tricyclic-bis-enones (tbes) |
| WO2008111497A1 (ja) | 2007-03-08 | 2008-09-18 | Santen Pharmaceutical Co., Ltd. | トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤 |
| WO2008136838A1 (en) | 2007-05-04 | 2008-11-13 | Trustees Of Dartmouth College | Novel amide derivatives of cddo and methods of use thereof |
| US8088824B2 (en) | 2007-08-15 | 2012-01-03 | Reata Pharmaceuticals Inc. | Forms of CDDO methyl ester |
| WO2009023845A2 (en) | 2007-08-15 | 2009-02-19 | The Board Of Regents Of The University Of Texas System | Combination therapy with synthetic triterpenoids and gemcitabine |
| US9012439B2 (en) | 2007-10-29 | 2015-04-21 | University Of Rochester | Use of electrophilic compounds for inducing platelet production or maintaining platelet function |
| KR101780382B1 (ko) * | 2008-01-11 | 2017-10-10 | 리타 파마슈티컬스 잉크. | 합성 트리테르페노이드 및 질병 치료시의 사용 방법 |
| RS58392B1 (sr) | 2008-04-18 | 2019-04-30 | Reata Pharmaceuticals Inc | Antioksidantni modulatori inflamacije: derivati oleanoličke kiseline sa amino i drugim modifikacijama na c-17 |
| CN102164941B (zh) | 2008-04-18 | 2015-05-27 | 里亚塔医药公司 | 抗氧化剂炎症调节剂:具有饱和c环的齐墩果酸衍生物 |
| RS55631B1 (sr) | 2008-04-18 | 2017-06-30 | Reata Pharmaceuticals Inc | Antioksidansni modulatori upale: c-17 homologisani derivati oleanolinske kiseline |
| US8071632B2 (en) * | 2008-04-18 | 2011-12-06 | Reata Pharmaceuticals, Inc. | Antioxidant inflammation modulators: novel derivatives of oleanolic acid |
| CN103588678A (zh) | 2008-04-18 | 2014-02-19 | 里亚塔医药公司 | 包含抗炎症药效团的化合物以及使用方法 |
| AU2009274037B2 (en) | 2008-07-22 | 2015-07-09 | Trustees Of Dartmouth College | Monocyclic cyanoenones and methods of use thereof |
| MX2011008344A (es) | 2009-02-13 | 2011-09-29 | Reata Pharmaceuticals Inc | Composiciones de dosis orales de liberacion retardada que contiene bardoloxona-metilo (cddo-me) amorfo. |
| AU2011240690C1 (en) | 2010-04-12 | 2014-11-06 | Reata Pharmaceuticals Holdings, LLC | Method of treating obesity using antioxidant inflammation modulators |
| US8618125B2 (en) | 2011-01-14 | 2013-12-31 | Heptiva LLC | Composition comprising hepatic therapeutic active for treating liver diseases, certain cancers and liver health maintenance |
| CN102875634B (zh) | 2012-10-24 | 2014-08-20 | 苏州晶云药物科技有限公司 | 2-氰基-3,12-二氧代齐墩果-1,9(11)-二烯-28-酸甲酯的几种晶型 |
| CN102887936A (zh) | 2012-10-24 | 2013-01-23 | 苏州晶云药物科技有限公司 | 2-氰基-3,12-二氧代齐墩果-1,9(11)-二烯-28-酸甲酯晶型 |
-
2011
- 2011-04-12 AU AU2011240690A patent/AU2011240690C1/en active Active
- 2011-04-12 SI SI201131840T patent/SI2558105T1/sl unknown
- 2011-04-12 EA EA201291031A patent/EA026567B1/ru not_active IP Right Cessation
- 2011-04-12 PH PH1/2012/502041A patent/PH12012502041B1/en unknown
- 2011-04-12 DK DK11715645.5T patent/DK2558105T3/da active
- 2011-04-12 EP EP11715645.5A patent/EP2558105B1/en active Active
- 2011-04-12 WO PCT/US2011/032156 patent/WO2011130302A2/en not_active Ceased
- 2011-04-12 CA CA2795320A patent/CA2795320C/en active Active
- 2011-04-12 MX MX2012011892A patent/MX357596B/es active IP Right Grant
- 2011-04-12 RS RS20200073A patent/RS59850B1/sr unknown
- 2011-04-12 TW TW100112717A patent/TWI558724B/zh not_active IP Right Cessation
- 2011-04-12 BR BR112012026112-6A patent/BR112012026112B1/pt active IP Right Grant
- 2011-04-12 PL PL11715645T patent/PL2558105T3/pl unknown
- 2011-04-12 HR HRP20192291TT patent/HRP20192291T1/hr unknown
- 2011-04-12 HU HUE11715645A patent/HUE047994T2/hu unknown
- 2011-04-12 NZ NZ602826A patent/NZ602826A/en unknown
- 2011-04-12 ME MEP-2020-4A patent/ME03713B/me unknown
- 2011-04-12 KR KR1020127029558A patent/KR101819699B1/ko active Active
- 2011-04-12 SM SM20200086T patent/SMT202000086T1/it unknown
- 2011-04-12 JP JP2013505061A patent/JP5990160B2/ja active Active
- 2011-04-12 CN CN201180028997.6A patent/CN102939089B/zh active Active
- 2011-04-12 SG SG2012075834A patent/SG184830A1/en unknown
- 2011-04-12 PT PT117156455T patent/PT2558105T/pt unknown
- 2011-04-12 ES ES11715645T patent/ES2768204T3/es active Active
- 2011-04-12 MY MYPI2012004530A patent/MY163031A/en unknown
- 2011-04-12 US US13/085,338 patent/US10105372B2/en active Active
- 2011-04-12 SG SG10201808661XA patent/SG10201808661XA/en unknown
- 2011-04-12 LT LTEP11715645.5T patent/LT2558105T/lt unknown
-
2012
- 2012-10-08 ZA ZA2012/07518A patent/ZA201207518B/en unknown
- 2012-10-09 IL IL222273A patent/IL222273B/en active IP Right Grant
- 2012-10-12 CL CL2012002859A patent/CL2012002859A1/es unknown
-
2018
- 2018-09-13 US US16/130,242 patent/US11911395B2/en active Active
-
2020
- 2020-01-09 CY CY20201100022T patent/CY1122480T1/el unknown
-
2024
- 2024-02-26 US US18/587,006 patent/US20240335457A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME03713B (me) | Bardoksolon meтil za lečenje gojaznosтi | |
| JP2010514831A5 (me) | ||
| JP2011527332A5 (me) | ||
| RU2017130849A (ru) | Дейтерированная производная хенодезоксихолевой кислоты и фармацевтическая композиция, содержащая данное соединение | |
| HRP20250732T1 (hr) | Kombinacija derivata 4-pirimidinsulfamida sa sglt-2 inhibitorom za liječenje bolesti povezanih s endotelinom | |
| JP2011511022A5 (me) | ||
| JP2011522816A5 (me) | ||
| JP2013509429A5 (me) | ||
| JP2009536191A5 (me) | ||
| JP2007504174A5 (me) | ||
| JP2018529779A5 (me) | ||
| JP2018513188A5 (me) | ||
| JP2009538898A5 (me) | ||
| JP2015508765A5 (me) | ||
| JP2008533127A5 (me) | ||
| JP2010520200A5 (me) | ||
| CA2648518A1 (en) | Treatment of hematological malignancies with fts and a bcr-abl tyrosine kinase inhibitor | |
| JP2017014206A5 (me) | ||
| JP2011046708A5 (me) | ||
| JP2013502420A5 (me) | ||
| JP2013501049A5 (me) | ||
| JP2010024244A5 (me) | ||
| JP2012506429A5 (me) | ||
| WO2007121545A8 (en) | S-nitrosothiols containing compositions for the treatment of fatty liver diseases, obesity and other diseases associated with the metabolic syndrome and the use of such compositions | |
| JP2017530182A5 (me) |